ATE483811T1 - Kontrollierte produktion und zuführung biologisch aktiver stoffe durch darmbakterien - Google Patents

Kontrollierte produktion und zuführung biologisch aktiver stoffe durch darmbakterien

Info

Publication number
ATE483811T1
ATE483811T1 AT06701043T AT06701043T ATE483811T1 AT E483811 T1 ATE483811 T1 AT E483811T1 AT 06701043 T AT06701043 T AT 06701043T AT 06701043 T AT06701043 T AT 06701043T AT E483811 T1 ATE483811 T1 AT E483811T1
Authority
AT
Austria
Prior art keywords
biologically active
supply
active substances
intestinal bacteria
controlled production
Prior art date
Application number
AT06701043T
Other languages
English (en)
Inventor
Simon Carding
Mark Farrar
Original Assignee
Univ Leeds
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leeds filed Critical Univ Leeds
Application granted granted Critical
Publication of ATE483811T1 publication Critical patent/ATE483811T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C12N1/16—Yeasts; Culture media therefor
    • C12N1/18—Baker's yeast; Brewer's yeast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Botany (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT06701043T 2005-01-25 2006-01-24 Kontrollierte produktion und zuführung biologisch aktiver stoffe durch darmbakterien ATE483811T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0501540.9A GB0501540D0 (en) 2005-01-25 2005-01-25 Controlled production and delivery of biologically active agents by gut bacteria
PCT/GB2006/000222 WO2006079790A2 (en) 2005-01-25 2006-01-24 Controlled production and delivery of biologically active agents by gut bacteria

Publications (1)

Publication Number Publication Date
ATE483811T1 true ATE483811T1 (de) 2010-10-15

Family

ID=34259652

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06701043T ATE483811T1 (de) 2005-01-25 2006-01-24 Kontrollierte produktion und zuführung biologisch aktiver stoffe durch darmbakterien

Country Status (10)

Country Link
US (1) US7988961B2 (de)
EP (1) EP1841875B1 (de)
JP (1) JP4989490B2 (de)
KR (1) KR101291960B1 (de)
AT (1) ATE483811T1 (de)
CA (1) CA2640343C (de)
DE (1) DE602006017331D1 (de)
ES (1) ES2353721T3 (de)
GB (1) GB0501540D0 (de)
WO (1) WO2006079790A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2740434C (en) * 2007-10-26 2017-11-07 Brenda E. Moore Probiotic compositions and methods for inducing and supporting weight loss
EP2258844A1 (de) 2009-05-28 2010-12-08 Helmholtz Zentrum Für Infektionsforschung Tumorspezifische bakterielle Promoterelemente
CN102462837B (zh) * 2010-11-19 2016-08-03 生物林格斯Ip有限公司 抗炎组合物
US10047405B2 (en) 2013-12-20 2018-08-14 President And Fellows Of Harvard College Engineered genetic enteric sensor bacteria and uses thereof
US9688967B2 (en) 2014-12-05 2017-06-27 Synlogic, Inc. Bacteria engineered to treat diseases associated with hyperammonemia
US20160206666A1 (en) 2014-12-22 2016-07-21 Synlogic, Inc. Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tighten gut mucosal barrier
AU2015369627A1 (en) * 2014-12-22 2017-07-06 Massachusetts Institute Of Technology Probiotic organisms for diagnosis, monitoring, and treatment of inflammatory bowel disease
MX385397B (es) * 2015-03-02 2025-03-18 Synlogic Operating Co Inc Bacteria manejada genéticamente para producir butirato, interleucina-10 y/o interleucina-22 para tratar enfermedades que se benefician de inflamación intestinal reducida y/o barrera mucosa intestinal fortalecida.
EP3294760B1 (de) 2015-05-13 2021-03-24 Synlogic Operating Company, Inc. Manipulierte bakterien zur behandlung einer krankheit oder einer störung
US11685925B2 (en) 2015-10-30 2023-06-27 Synlogic Operating Company, Inc. Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier
WO2017087580A1 (en) 2015-11-16 2017-05-26 Synlogic, Inc. Bacteria engineered to reduce hyperphenylalaninemia
EP3445857B1 (de) * 2016-04-20 2023-07-05 The Board of Trustees of the Leland Stanford Junior University Zusammensetzungen und verfahren zur nukleinsäureexpression und proteinsekretion bei bakteroiden
AU2017376780B2 (en) 2016-12-15 2024-12-12 Novome Biotechnologies, Inc. Compositions and methods for modulating growth of a genetically modified gut bacterial cell
US11224624B2 (en) * 2017-02-14 2022-01-18 California Institute Of Technology Modulation of microbial synthesis of 4-etylphenol and 4-ethylphenyl sulfate in behavior and disease
US20200268813A1 (en) * 2017-02-15 2020-08-27 President And Fellows Of Harvard College Modulation of host immune cell populations using gut microbiota
EP3600365A4 (de) 2017-03-29 2021-01-06 President and Fellows of Harvard College Verfahren zur regelung der genexpression in einer zelle
CN110709093A (zh) * 2017-04-17 2020-01-17 加利福尼亚大学董事会 工程化细菌和使用方法
AU2018290278B2 (en) 2017-06-21 2022-12-15 Synlogic Operating Company, Inc. Bacteria for the treatment of disorders
US12421518B2 (en) 2018-12-10 2025-09-23 Tenza, Inc. Methods and compositions for treating hyperoxaluria
JP2023518184A (ja) 2020-03-20 2023-04-28 シンロジック オペレーティング カンパニー インコーポレイテッド 高フェニルアラニン血症を軽減するように遺伝子改変された微生物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0569604A1 (de) * 1992-04-07 1993-11-18 Societe Des Produits Nestle S.A. Integrative Genexpression in Streptococcus sulivarius ssp. thermophilus
JP2003509046A (ja) * 1999-09-10 2003-03-11 イギリス国 組換え微生物
JP2001275680A (ja) * 2000-03-31 2001-10-09 Yakult Honsha Co Ltd β−１，３−キシラナーゼ遺伝子、該遺伝子を導入した微生物、及びβ−１，３−キシラナーゼの製造法
JP2003144200A (ja) * 2001-11-07 2003-05-20 Yakult Honsha Co Ltd バクテロイデスグループ細菌用プローブおよびこれを用いた検出方法

Also Published As

Publication number Publication date
WO2006079790A3 (en) 2006-12-21
US7988961B2 (en) 2011-08-02
KR20070108882A (ko) 2007-11-13
WO2006079790A2 (en) 2006-08-03
JP4989490B2 (ja) 2012-08-01
GB0501540D0 (en) 2005-03-02
EP1841875A2 (de) 2007-10-10
US20080131402A1 (en) 2008-06-05
CA2640343C (en) 2014-01-14
ES2353721T3 (es) 2011-03-04
DE602006017331D1 (de) 2010-11-18
JP2008527988A (ja) 2008-07-31
EP1841875B1 (de) 2010-10-06
CA2640343A1 (en) 2006-08-03
KR101291960B1 (ko) 2013-08-09

Similar Documents

Publication Publication Date Title
DE602006017331D1 (de) Kontrollierte produktion und zuführung biologisch aktiver stoffe durch darmbakterien
NL301089I2 (nl) imlifidase
BR112012017345A2 (pt) "composições e métodos de pgl para a produção aumentada de isopreno e outros produtos com 6-fosfogliconolactonase (pgl)"
MX2009013137A (es) Metodos para seleccionar polipeptidos resistentes a la proteasa.
MX2010002716A (es) Uso de slit, nefrina, efrina o semaforina para el tratamiento de enfermedades de cartilago.
PE20130593A1 (es) DOMINIOS DE FIBRONECTINA TIPO III A LA DECIMA (10Fn3) MODIFICADOS DE UNION A SEROALBUMINA
EA201171220A1 (ru) Мутанты fgf21 и их применение
EA201001883A1 (ru) Мутанты fgf21 и их применение
CL2012000063A1 (es) Polipéptido factor ix (fix) o un fragmento del mismo porque comprende la modificación de un aminoácido; vector; célula; método para expresar el polipéptido fix; composición farmacéutica; uso de la composición para tratar enfermedades trombóticas, hemorrágicas y coagulación intravascular diseminada (cid) (div. sol. 1796-07).
EA201590525A1 (ru) Слитые белки для лечения метаболического синдрома
MY159433A (en) Fibrous materials and compositions
PE20110310A1 (es) Axmi-115, axmi-113, axmi-005, axmi-163 y axmi-184: proteinas insecticidas
ES2534744T3 (es) Plasmina modificada de forma recombinante
NZ629649A (en) Toxic peptide production, peptide expression in plants and combinations of cysteine rich peptides
BR112013010487A2 (pt) novos substratos de coelenterazina e métodos de uso
GB0514779D0 (en) Biological products
MY180672A (en) Ace2 polypeptide
CO6430475A2 (es) Polipéptidos que tienen actividad de celulasa
MY148447A (en) Method for amidating polypeptides with basic aminoacid d-terminals by means of specific endoproteases
NO20082345L (no) Selektive VPAC2 reseptorpeptidagonister
EA201290542A1 (ru) Модифицированные свиные соматотропиновые полипептиды и их применение
EA201290541A1 (ru) Модифицированные бычьи соматотропиновые полипептиды и их применение
NZ596501A (en) Casb7439 constructs
ES2585185T3 (es) Polipéptidos quiméricos y sus aplicaciones terapéuticas contra una infección por Flaviviridae
SG10201803541TA (en) Biologically active c-terminal arginine-containing peptides

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties